All In Biotech

Drug Trial Radar · NCT04966702

Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)

A Phase III Cluster-randomized, Open-label, Clinical Trial to Study the Safety and Efficacy of Ivermectin Mass Drug Administration to Reduce Malaria Transmission in Two African Settings

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 48,145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

48,145

Actual

Start

Mar 17, 2022

Primary completion

Apr 15, 2024

Study completion Oct 3, 2024

Sponsor

Lead sponsor
Barcelona Institute for Global HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
UNITAID
First posted
Jul 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 week, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The BOHEMIA program consists of a combination of studies organized around a central community prevention mass drug administration protocol and four sub-studies (i.e.; social science, entomology, health economics, and environmental), each written as an individual protocol. The protocol is central but used in two separate, individually powered trials in Mozambique and Kenya. The trials have been powered on the efficacy outcome and designed to meet the requirements of World Health Organization's (WHO) preferred product characteristics (PPC) for endectocides.

Conditions

  • Malaria

Interventions

  • Albendazole PillDrug

    Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants

  • Ivermectin PillDrug

    Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants

  • Ivermectin Injectable ProductDrug

    Veterinary ivermectin injectable will be given to livestock in the relevant cluster

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the safety (in humans) and efficacy of ivermectin MDA, administered to humans, or humans and livestock simultaneously (only in Mozambique) for the prevention of malaria.Time frame: 6 months
  2. To determine the safety (in humans) and efficacy of ivermectin MDA, administered to humans, or humans and livestock simultaneously (only in Mozambique) for the prevention of malaria.Time frame: 6 months

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • KEMRI

    Kwale, Kenya

  • CISM

    Mopeia, Zambezia Province, Mozambique

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.